Literature DB >> 314829

Lupus-type illness associated with labetalol.

I D Griffiths, J Richardson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 314829      PMCID： PMC1595989          DOI： 10.1136/bmj.2.6188.496-d

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  6 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Hypotensive agents, beta-blockers, and drug-induced lupus.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-08

3.  SLE syndrome, probably induced by labetalol.

Authors:  R C Brown; J Cooke; M S Losowsky
Journal:  Postgrad Med J       Date:  1981-03       Impact factor: 2.401

4.  Fatal bone-marrow suppression associated with captopril.

Authors:  M E Safar
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-19

Review 5.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 6.  Acetylator phenotype and lupus erythematosus.

Authors:  J P Uetrecht; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.